CurrentColorado Rocky Mountain Health PlansPolicy N/A

Opfolda (miglustat) — prior authorization for late-onset Pompe disease

Defines prior authorization requirements for coverage of Opfolda (miglustat) in combination with Pombiliti for adults with late-onset Pompe disease under UnitedHealthcare Pharmacy clinical programs; applies to providers requesting pharmacy benefit authorization.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyOpfolda (miglustat) — prior authorization for late-onset Pompe disease

Policy CodePolicy N/A

Change TypeClarified (no material change)

Effective DateFeb 15, 2026

Next Review DateNov 20, 2025

Key ActionObtain prior authorization for Pombiliti and document diagnosis of late-onset Pompe disease to request Opfolda.

SourceLink

POLICY UPDATE CHANGES

Clarified criteria without change to clinical intent and updated references.

12 monthsauthorization duration

≥40 kgweight requirement

Pombiliti requiredcombination therapy

positive responsereauthorization

Coverage Criteria for Opfolda (miglustat)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy — Covered when ALL of the following are met

Covered when ALL of the following are met:

Initial Authorization

Diagnosis of late-onset Pompe disease.
Patient has an active UnitedHealthcare medical benefit prior authorization for Pombiliti (cipaglucosidase alfa-atga) for the treatment of late-onset Pompe disease.

Continuation/Reauthorization — Covered when ALL of the following are met

Covered when ALL of the following are met:

Reauthorization

Documentation of positive clinical response to Opfolda plus Pombiliti.
Opfolda continues to be prescribed in combination with Pombiliti.

This policy covers Opfolda (miglustat) only for adult patients diagnosed with late-onset Pompe disease (lysosomal acid alpha‑glucosidase [GAA] deficiency) who weigh at least 40 kg. Coverage is limited to use in combination with Pombiliti (cipaglucosidase alfa‑atga); Opfolda prescribed without concomitant Pombiliti is outside the scope of this policy. Initial approval requires documentation of the diagnosis and that the member has an active UnitedHealthcare medical benefit prior authorization for Pombiliti. Reauthorization requires documentation of a positive clinical response to the combination and continued co‑prescription with Pombiliti. Authorization, when issued, is for 12 months.

Initial Therapy

Initial Therapy — Initial coverage requires both conditions below

Initial coverage requires both conditions below:

Initial

Diagnosis of late-onset Pompe disease.
Active UnitedHealthcare medical benefit prior authorization for Pombiliti (cipaglucosidase alfa-atga).

Continuation / Reauthorization Criteria

Continuation Therapy — Reauthorization rules

Reauthorization rules:

Reauthorization

Documentation of positive clinical response to Opfolda plus Pombiliti.
Ongoing prescription of Opfolda in combination with Pombiliti (cipaglucosidase alfa-atga).

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required before initiating Opfolda (cipaglucosidase alfa).

Diagnosis: late-onset Pompe disease
Active UnitedHealthcare medical benefit prior authorization for Pombiliti (cipaglucosidase alfa-atga) for treatment of late-onset Pompe disease
Authorization duration: 12 months

Note

Automated Approval Note

Initial approvals and reauthorizations may be granted automatically based on available claims/medication history, diagnosis codes (ICD-10), and embedded claim logic. Automated processes and applicability vary by program and therapeutic class.

Use of automated approval/re-approval varies by program and therapeutic class
Approvals may be based solely on prior claim/medication history and diagnosis codes

Documentation Required

Required Documentation for Reauthorization

For reauthorization, submit documentation demonstrating continued clinical benefit and that therapy remains prescribed in combination with Pombiliti.

Documentation of positive clinical response to Opfolda plus Pombiliti
Evidence that Opfolda continues to be prescribed in combination with Pombiliti
Authorization duration on reauthorization: 12 months

Denial Risk

Triggers for Denial

Denial triggers include missing or insufficient documentation of the required diagnosis or lack of the required UnitedHealthcare medical benefit prior authorization for Pombiliti.

No documented diagnosis of late-onset Pompe disease
No active UnitedHealthcare medical benefit prior authorization for Pombiliti
Missing documentation of positive clinical response on reauthorization

Background and Indication

Opfolda (miglustat) is described in the prescribing context as an enzyme stabilizer used adjunctively with Pombiliti, a hydrolytic lysosomal glycogen‑specific enzyme. The indication in the source specifies treatment of adult patients with late‑onset Pompe disease who weigh ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). The policy ties coverage of Opfolda to concurrent treatment with and authorization for Pombiliti under the member’s UnitedHealthcare medical benefit.

Key Definitions

inv-09: Late-onset Pompe disease — definition and brief clinical description

DefinitionLate-onset Pompe disease: a lysosomal acid alpha-glucosidase (GAA) deficiency causing progressive muscle weakness (adult-onset form).

Key clinical featureProgressive muscle weakness due to GAA deficiency; manifests in adults as late-onset Pompe disease.

Indication contextOpfolda (miglustat) is indicated as adjunctive therapy in combination with Pombiliti for adult patients with late-onset Pompe disease who weigh ≥40 kg and are not improving on current enzyme replacement therapy (ERT).

Patient populationAdults (weighing ≥40 kg) with late-onset Pompe disease who have inadequate response to ERT.